A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Alisertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 Jan 2017 Last checked against ClinicalTrials.gov record.
- 19 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.